Rationale and design of MultiSELECt: A European Multi center S tudy on the E ffect of L ipoprotein(a) E limination by lipoprotein apheresis on C ardiovascular ou t comes

Nichols, 2013, Cardiovascular disease in Europe: epidemiological update, Eur Heart J, 34, 3028, 10.1093/eurheartj/eht356 Julius, 2013, Updates in apheresis and atherosclerotic research, Therapeutic apheresis and dialysis: official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 17, 124, 10.1111/1744-9987.12029 Ross, 1999, Atherosclerosis–an inflammatory disease, N Engl J Med, 340, 115, 10.1056/NEJM199901143400207 Castelli, 1984, Epidemiology of coronary heart disease: the Framingham study, Am J Med, 76, 4, 10.1016/0002-9343(84)90952-5 Pullinger, 2003, Primary hypercholesterolemia: genetic causes and treatment of five monogenic disorders, Expert Rev Cardiovasc Ther, 1, 107, 10.1586/14779072.1.1.107 Sabatine, 2015, Efficacy and safety of evolocumab in reducing lipids and cardiovascular events, N Engl J Med, 372, 1500, 10.1056/NEJMoa1500858 Robinson, 2015, Efficacy and safety of alirocumab in reducing lipids and cardiovascular events, N Engl J Med, 372, 1489, 10.1056/NEJMoa1501031 Fischer, 2013, Current standards in diagnosis and therapy of hyperlipoproteinemia, Atheroscler Suppl, 14, 15, 10.1016/j.atherosclerosissup.2012.10.035 Kamstrup, 2012, Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis, Arteriosclerosis, Thromb Vasc Biol, 32, 1732, 10.1161/ATVBAHA.112.248765 Nordestgaard, 2010, Lipoprotein(a) as a cardiovascular risk factor: current status, Eur Heart J, 31, 2844, 10.1093/eurheartj/ehq386 Kamstrup, 2008, Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study, Circulation, 117, 176, 10.1161/CIRCULATIONAHA.107.715698 Kamstrup, 2013, Lipoprotein(a) concentrations, isoform size, and risk of type 2 diabetes: a Mendelian randomisation study, Lancet Diabetes Endocrinol, 1, 220, 10.1016/S2213-8587(13)70064-0 Kamstrup, 2014, Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population, J Am Coll Cardiol, 63, 470, 10.1016/j.jacc.2013.09.038 Kamstrup, 2013, Extreme lipoprotein(a) levels and improved cardiovascular risk prediction, J Am Coll Cardiol, 61, 1146, 10.1016/j.jacc.2012.12.023 Leebmann, 2013, Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study, Circulation, 128, 2567, 10.1161/CIRCULATIONAHA.113.002432 Federal Joint Committee. Transactions of the German Federal Ministries. BAnz;138:3321. Jaeger, 2009, Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events, Nat Clin Pract Cardiovasc Med, 6, 229, 10.1038/ncpcardio1456 Safarova, 2013, Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography, Atheroscler Suppl, 14, 93, 10.1016/j.atherosclerosissup.2012.10.015 von Dryander, 2013, Differences in the atherogenic risk of patients treated by lipoprotein apheresis according to their lipid pattern, Atheroscler Suppl, 14, 39, 10.1016/j.atherosclerosissup.2012.10.005 Emmrich, 2015, Actual situation of lipoprotein apheresis in Saxony in 2013, Atheroscler Suppl, 18, 215, 10.1016/j.atherosclerosissup.2015.02.034 Heigl, 2015, Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: findings gathered from more than 36,000 treatments at one center in Germany, Atheroscler Suppl, 18, 154, 10.1016/j.atherosclerosissup.2015.02.013 Rosada, 2014, Does regular lipid apheresis in patients with isolated elevated lipoprotein(a) levels reduce the incidence of cardiovascular events?, Artif Organs, 38, 135, 10.1111/aor.12135 Marcovina, 2016, Lp(a) measurements for clinical application, J Lipid Res, 57, 526, 10.1194/jlr.R061648 Julius, 2013, Why an apheresis center should offer more than one lipoprotein apheresis method, Ther Apher Dial: official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 17, 179, 10.1111/j.1744-9987.2012.01129.x Moriarty, 2016, Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial, Eur Heart J, 37, 3588, 10.1093/eurheartj/ehw388 Roeseler, 2016, Lipoprotein apheresis for lipoprotein(a)-associated cardiovascular disease: prospective 5 years of follow-up and apolipoprotein(a) characterization, Arteriosclerosis, Thromb, Vasc Biol, 36, 2019, 10.1161/ATVBAHA.116.307983